Drug intelligence / Profile preview

D13

Development stage: Preclinical
Lead developer: Antiverse
Modality: Antibody-Based Therapeutics

Overview

D13 is an anti-PD-1 antibody developed through a collaboration between Antiverse, a UK-based company with an AI antibody discovery platform, and GlobalBio, a US-based antibody engineering company. This antibody is designed for cancer therapy and is notable for its cross-reactivity with human, mouse, dog, and cynomolgus PD-1 orthologs, demonstrating functional blocking activity. It is currently in preclinical development, aiming to develop novel antibody therapeutics for the immuno-oncology market for both humans and animals.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on D13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D13.

Explore the full profile